HUMACYTE INC(NASDAQ:HUMA) stock News

HUMA Latest News, Press Relases and Analysis

All

Press Releases

2 days ago - By: Chartmill - Mentions: RVSN SPRB BMEA SGLY ...

Top stock movements in today's session.

2 days ago - By: Chartmill - Mentions: BTM AEHR APVO PCSA ...

Which stocks are moving on Tuesday?

2 days ago - By: Benzinga - Mentions: SNWV CLRB APVO SPRB ...

12 Health Care Stocks Moving In Tuesday's Intraday Session

2 days ago - By: Chartmill - Mentions: NAK ACET BTM AEHR ...

Tuesday's session: gap up and gap down stocks

3 days ago - By: Humacyte, Inc

Humacyte Announces Publication of Long-Term Results for Ukrainian Patients Treated in Real-World Combat Setting with Symvess™

8 days ago - By: Zacks Investment Research

Humacyte, Inc. (HUMA) Outperforms Broader Market: What You Need to Know

21 days ago - By: Humacyte, Inc

Humacyte Announces Publication of Preclinical Data on Use of the CTEV as a Coronary Artery Bypass Graft (CABG)

24 days ago - By: Humacyte, Inc

Humacyte Announces Publication of Outcomes for Patients with Hospital-Acquired Vascular Complications Treated with Symvess™

2 months ago - By: Zacks Investment Research

Is It Worth Investing in Humacyte, Inc. (HUMA) Based on Wall Street's Bullish Views?

2 months ago - By: Zacks Investment Research - Mentions: EDIT

Humacyte, Inc. (HUMA) Reports Q2 Loss, Misses Revenue Estimates

2 months ago - By: The Motley Fool

Humacyte Posts Q2 Revenue Miss

2 months ago - By: Humacyte, Inc

Humacyte Announces Second Quarter 2025 Financial Results and Provides Business Update

2 months ago - By: Benzinga

An Overview of Humacyte's Earnings

2 months ago - By: Zacks Investment Research

Humacyte, Inc. (HUMA) Stock Dips While Market Gains: Key Facts

2 months ago - By: Zacks Investment Research

Humacyte, Inc. (HUMA) Suffers a Larger Drop Than the General Market: Key Insights

3 months ago - By: Zacks Investment Research - Mentions: SBUX ORCL ITW ICE ...

Beat the Market the Zacks Way: Humacyte, Starbucks, Oracle in Focus

4 months ago - By: Humacyte, Inc

Results from Humacyte’s V007 Pivotal Phase 3 AV Access Study Highlighted by Presentation at the Society for Vascular Surgery Meeting

4 months ago - By: Humacyte, Inc

Humacyte Clinical Results in High-Risk Dialysis Patients from V007 Pivotal Phase 3

4 months ago - By: Zacks Investment Research

Is Humacyte, Inc. (HUMA) a Buy as Wall Street Analysts Look Optimistic?

5 months ago - By: Humacyte, Inc

Humacyte to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq

5 months ago - By: Zacks Investment Research - Mentions: IRD

Humacyte, Inc. (HUMA) Reports Q1 Loss, Lags Revenue Estimates

5 months ago - By: Humacyte, Inc

Humacyte Announces First Quarter 2025 Financial Results and Provides Business Update

5 months ago - By: Humacyte, Inc

HUMACYTE INC (HUMA) Stock News

HUMA Latest News, Press Relases and Analysis

Top stock movements in today's session.

Which stocks are moving on Tuesday?

12 Health Care Stocks Moving In Tuesday's Intraday Session

Tuesday's session: gap up and gap down stocks

Humacyte Announces Publication of Long-Term Results for Ukrainian Patients Treated in Real-World Combat Setting with Symvess™

Humacyte, Inc. (HUMA) Outperforms Broader Market: What You Need to Know

Humacyte Announces Publication of Preclinical Data on Use of the CTEV as a Coronary Artery Bypass Graft (CABG)

Humacyte Announces Publication of Outcomes for Patients with Hospital-Acquired Vascular Complications Treated with Symvess™

Is It Worth Investing in Humacyte, Inc. (HUMA) Based on Wall Street's Bullish Views?

Humacyte, Inc. (HUMA) Reports Q2 Loss, Misses Revenue Estimates

Humacyte Posts Q2 Revenue Miss

Humacyte Announces Second Quarter 2025 Financial Results and Provides Business Update

An Overview of Humacyte's Earnings

Humacyte, Inc. (HUMA) Stock Dips While Market Gains: Key Facts

Humacyte, Inc. (HUMA) Suffers a Larger Drop Than the General Market: Key Insights

Beat the Market the Zacks Way: Humacyte, Starbucks, Oracle in Focus

Results from Humacyte’s V007 Pivotal Phase 3 AV Access Study Highlighted by Presentation at the Society for Vascular Surgery Meeting

Humacyte Clinical Results in High-Risk Dialysis Patients from V007 Pivotal Phase 3

Is Humacyte, Inc. (HUMA) a Buy as Wall Street Analysts Look Optimistic?

Humacyte to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq

Humacyte, Inc. (HUMA) Reports Q1 Loss, Lags Revenue Estimates

Humacyte Announces First Quarter 2025 Financial Results and Provides Business Update

Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 13, 2025